Tau (MAPT) Human shRNA Plasmid Kit (Locus ID 4137)

Specifications

Product Data
Product Name	Tau (MAPT) Human shRNA Plasmid Kit (Locus ID 4137)
Locus ID	4137
UniProt ID	P10636
Synonyms	DDPAC; FTDP-17; MAPTL; MSTD; MTBT1; MTBT2; PPND; PPP1R103; TAU; tau-40
Vector	pGFP-C-shLenti
Format	Lentiviral plasmids
Kit Components	MAPT - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector(Gene ID = 4137). 5µg purified plasmid DNA per construct 29-mer scrambled shRNA cassette in pGFP-C-shLenti Vector, TR30021, included for free.
RefSeq	NM_001123066, NM_001123067, NM_001203251, NM_001203252, NM_005910, NM_016834, NM_016835, NM_016841, NM_173727, NM_005910.2, NM_005910.3, NM_005910.4, NM_005910.5, NM_016841.1, NM_016841.2, NM_016841.3, NM_016841.4, NM_016835.1, NM_016835.2, NM_016835.3, NM_016835.4, NM_016834.1, NM_016834.2, NM_016834.3, NM_016834.4, NM_001123067.1, NM_001123067.2, NM_001123067.3, NM_001123066.1, NM_001123066.2, NM_001123066.3, NM_001203251.1, NM_001203252.1, NM_173727.1, BC114948, BC000558, BC032572, BC040444, BC061892, BC071830, BC094805, BC098281, BC099721, BC101936, BC114504, NM_016841.5, NM_001203251.2, NM_016834.5
Summary	This gene encodes the microtubule-associated protein tau (MAPT) whose transcript undergoes complex, regulated alternative splicing, giving rise to several mRNA species. MAPT transcripts are differentially expressed in the nervous system, depending on stage of neuronal maturation and neuron type. MAPT gene mutations have been associated with several neurodegenerative disorders such as Alzheimer's disease, Pick's disease, frontotemporal dementia, cortico-basal degeneration and progressive supranuclear palsy. [provided by RefSeq, Jul 2008]
shRNA Design	These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact techsupport@origene.com. If you need a special design or shRNA sequence, please utilize our custom shRNA service.
Performance Guaranteed	OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples. For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).

*Delivery time may vary from web posted schedule. Occasional delays may occur due to unforeseen complexities in the preparation of your product. International customers may expect an additional 1-2 weeks in shipping.